As cancer diagnostics firm Neoprobe (NYSE Amex: NEOP) marches toward FDA approval of its “game-changing” radiopharmaceutical Lymphoseek and its share price continues to climb, many of the company’s ...

There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on September 15, Neoprobe Corp.'s Director, Peter F Drake, ...

Neoprobe (NYSE Amex: NEOP) remains on track to file a New Drug Application for its drug used for cancer detection, Lymphoseek, sometime in the third quarter. Factoring in the customary 10-month review ...

Earlier this month, Neoprobe (ASE: NEOP) completed the sale of its handheld gamma radiation detector business to Devicor Medical Products. The company pocketed $30 million up-front with the potential ...

DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that its common stock has been ...

DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today released the text of its ...

DUBLIN, Ohio--(BUSINESS WIRE)-- On Friday, July 22, 2011, it was disclosed in a private company press release that the U.S. Food and Drug Administration (FDA) had approved use of sulfur colloid (Kit ...

It took 17 years, but Neoprobe Corp. has turned a profit. But product development expenses and the structure of Neoprobe's contract with its marketing partner will make a trip back to the black a ...

“The Lymphoseek NDA marks a significant clinical and regulatory milestone for our novel, receptor-targeted radiopharmaceutical agent, Lymphoseek, that has undergone extensive clinical evaluation over ...

Neoprobe Corp. reported a net loss in the third quarter as it sought additional funding. Neoprobe lost $1.1 million, or 3 cents a share, on revenue of $920,000 in the third quarter of 2002. That ...

Earlier this month, Neoprobe (AMEX: NEOP) completed the sale of its handheld gamma radiation detector business to Devicor Medical Products. The company pocketed $30 million up-front with the potential ...